Zydus Lifesciences Ltd received final approval from the US Food and Drug Administration (USFDA) to market its generic version of Dapsone gel 7.5% for acne treatment. The gel is manufactured at their facility in Ahmedabad. Dapsone gel 7.5% had annual sales of $35.8 million in the US, according to IQVIA MAT March 2024 data, as reported in a regulatory filing.
